This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Merck & Company: Product KL-798
Frey, Sherwood C. Jr.; Bodily, Samuel E.Case DARDEN-QA-0582-EDecision AnalysisMerck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.Starting at €8.20
-
George's T-Shirts
Frey, Sherwood C. Jr.; Pfeifer, Phillip E.Case DARDEN-QA-0346-EDecision AnalysisGeorge Lasiter sells special-events T-shirts and must decide how many to order for an upcoming concert. He has high, medium, and low estimates of both concert attendance and the percentage of attendees who will want a shirt. In addition, he has assessed the relative likelihoods of each estimate. The case can be used to introduce or reinforce the fundamental issues surrounding decision making under uncertainty.Starting at €8.20
-
Merck & Company: Product KL-798 (Spanish version)
Frey, Sherwood C. Jr.; Bodily, Samuel E.Case DARDEN-QA-0910Decision AnalysisEsta es una traducción al español de la versión del 14 de junio de 2016 del caso UVA-QA-0582. Merck ha sido contactado por una pequeña empresa de investigación en biotecnología con una propuesta para que Merck compre los derechos de un nuevo medicamento que promete tratar la obesidad y reducir el colesterol. El medicamento se encuentra en la mitad de la fase I del proceso de aprobación de la FDA. Pat Harlow, el director de licencias, ha estado al...Starting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Madison House: Riley Carter
Frey, Sherwood C. Jr.; Bass, Lucien; Grant, MaxCase DARDEN-QA-0803-EDecision AnalysisThis two-part negotiation exercise is used in Negotiations electives at both the Darden School of Business and the McIntire School of Commerce. Together the cases provide the background for a scorable, bilateral, multi-issue negotiation in which there are congruent, distributive, and integrative issues. People and Congregations Engaged in Ministry (PACEM) was a nonprofit organization committed to helping homeless adults in the Charlottesville, Vi...Starting at €8.20
-
PACEM: Kennedy Brooks
Frey, Sherwood C. Jr.; Bass, Lucien; Grant, MaxCase DARDEN-QA-0802-EDecision AnalysisThis two-part negotiation exercise is used in Negotiations electives at both the Darden School of Business and the McIntire School of Commerce. Together, the cases provide the background for a scorable, bilateral, multi-issue negotiation in which there are congruent, distributive, and integrative issues. People and Congregations Engaged in Ministry (PACEM) was a nonprofit organization committed to helping homeless adults in the Charlottesville, V...Starting at €8.20
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCase HBS-815114-EEntrepreneurshipIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Starting at €8.20
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCase HBS-813091-EEntrepreneurshipSupplement for case 809011Starting at €8.20
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCase HBS-810027-EEntrepreneurshipNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Starting at €8.20
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCase HBS-818068-EStrategyStarting at €8.20